For anyone in Sénas looking to source CJC-1295, the first thing to know is that this compound is distributed via specialist online vendors. What this means for Sénas researchers is that your location matters far less than your ability to evaluate vendor quality — and those evaluation tools are available to every researcher. The core quality markers for CJC-1295 are HPLC purity ≥98%, molecular identity confirmed by mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. The sections below cover what Sénas researchers need to know about finding, evaluating, and storing CJC-1295 for legitimate research applications.
CJC-1295: What the Research Shows
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Sénas studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Source CJC-1295 — Vendor Guide
Vetting CJC-1295 vendors begins with the COA: locate the batch-specific certificate before purchasing, not after. A COA for CJC-1295 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. Community reputation in research forums is a useful additional signal to COA verification — vendors with sustained positive community feedback have proved themselves through consistent results. Keep lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the amount needed for the near-term protocol and keep the remainder frozen.
Order CJC-1295 — ships to Sénas
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and limited human studies. Storage requirements for CJC-1295: lyophilised powder at minus 20°C, reconstituted solution kept at 2-8°C refrigerated and consumed within 4 weeks; reconstitute only with sterile bacteriostatic water. Quality CJC-1295 sourcing directly determines safety outcomes — bacterial endotoxin contamination, mislabeling, and degradation products are all safety issues that verified-quality sourcing directly prevents. For any individual considering CJC-1295 outside a formal research context: speak with a healthcare professional — this compound is not approved for human use and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
